In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 41 for your search:
Drug:  thalidomide
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SHCZH-2010-CT-001, NCT01249690

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-3, NCT01664975

3.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 80
Sponsor: Other
Protocol IDs: A-39/29.1.2007, ICMR No-5/8/7/26/99-ECD-I, NCT00522405

4.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: RFA005, NCT00728078

5.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004LS001, MT2003-13, 0312M54569, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00293306, NCT00177047

6.

Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: ICMR- D.O No.5/8/7/26/99-ECD-1, NCT01438450

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MHOPES-myeloma09, NCT00892346

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: LCI-THALIDOMIDE, LCI-09-06-15, NCT00921531

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018751, 26866138-MMY-2073, NCT01539083

11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT number: 2009-010956-93, NCT01554852

12.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 5 to 18
Sponsor: Other
Protocol IDs: IEC/NP-63/2013, NCT01858571

13.

Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Other
Protocol IDs: RC13_0284, 2013-003174-27, NCT01971658

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NKT-SYSUCC-2013, NCT02085655

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: 931003, NCT00155272

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HM12/10174, NCT02145715

17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: T-CID, NCT00124813

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: KMM55, NCT00319865

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: KMM53, NCT00349115

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: KMM51, 26866138MMY2028, NCT00378755

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FEMH-94037, NCT00384800

22.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: TMZ/05, P04932, NCT00521482

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 0707009285, RV-MM-PI-238, NCT00538733

24.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: TASMC-08-MM-TLV-0069-08-CTIL, NCT00704704

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: Auto-Allo TSCT in MM, NCT00777998
1   
New Search